



	400.0 μM ATP	300 μM ATP	200 μM ATP	150 μM ATP	100 μM ATP	50 μM ATP	25 μM ATP	12.5 μM ATP
IC50	2.515e-008	2.285e-008	1.343e-008	9.878e-009	1.163e-008	1.019e-008	1.031e-008	1.011e-008



	300.0 μM ATP	250 μM ATP	200 μM ATP	150 μM ATP	100 μM ATP	50 μM ATP	25 μM ATP	12.5 μM ATP
IC50	9.449e-008	1.635e-007	5.782e-008	4.956e-008	5.649e-008	6.420e-008	1.310e-007	1.885e-007



Supplementary figure 1: (A-B) IC50 of Idelalisib (A) and IOA-244 (B) derived from the ATP competition assay shown in Figure 1C and 1D respectively. (C) Representation of the selectivity of the represented PI3Kδ inhibitors and Idelalisib main metabolite GS-563117 using partition index based on IC50 values in Jurkat cell lysate as measured by KiNativ assay.